| SC 13G/A | 2017-01-23 | BlackRock Inc. | Celldex Therapeutics, Inc. | 7,889,061 | 7.8% | EDGAR |
| SC 13G | 2016-12-09 | KLP Enterprises, LLC | Celldex Therapeutics, Inc. | 6,865,006 | 5.7% | EDGAR |
| SC 13G | 2016-04-08 | STATE STREET CORP | Celldex Therapeutics, Inc. | - | 8.7% | EDGAR |
| SC 13G/A | 2016-02-12 | FMR LLC | Celldex Therapeutics, Inc. | 14,796,853 | 15.0% | EDGAR |
| SC 13G/A | 2016-02-10 | VANGUARD GROUP INC | Celldex Therapeutics, Inc. | 6,791,275 | 6.9% | EDGAR |
| SC 13G/A | 2016-02-04 | FRANKLIN RESOURCES INC | Celldex Therapeutics, Inc. | 9,804,892 | 9.9% | EDGAR |
| SC 13G/A | 2016-02-02 | OppenheimerFunds, Inc. | Celldex Therapeutics, Inc. | 8,901,692 | 9.0% | EDGAR |
| SC 13G | 2016-01-27 | FIRST TRUST PORTFOLIOS LP | Celldex Therapeutics, Inc. | 7,424,420 | 7.5% | EDGAR |
| SC 13G/A | 2016-01-26 | BlackRock Inc. | Celldex Therapeutics, Inc. | 6,547,643 | 6.6% | EDGAR |
| SC 13G/A | 2015-02-13 | FMR LLC | Celldex Therapeutics, Inc. | 13,438,365 | 15.0% | EDGAR |
| SC 13G/A | 2015-02-10 | VANGUARD GROUP INC | Celldex Therapeutics, Inc. | 5,405,353 | 6.0% | EDGAR |
| SC 13G/A | 2015-02-09 | FRANKLIN RESOURCES INC | Celldex Therapeutics, Inc. | 9,570,072 | 10.7% | EDGAR |
| SC 13G/A | 2015-01-29 | BlackRock Inc. | Celldex Therapeutics, Inc. | 6,304,877 | 7.0% | EDGAR |
| SC 13G/A | 2014-04-10 | FRANKLIN RESOURCES INC | Celldex Therapeutics, Inc. | 9,883,257 | 11.1% | EDGAR |
| SC 13G/A | 2014-02-14 | FMR LLC | Celldex Therapeutics, Inc. | 12,157,327 | 13.7% | EDGAR |
| SC 13G/A | 2014-02-14 | SAC Capital Advisors LP | Celldex Therapeutics, Inc. | 3,506,488 | 3.9% | EDGAR |
| SC 13G/A | 2014-02-14 | Ridgeback Capital Investments L.P. | Celldex Therapeutics, Inc. | 1,025,000 | 1.3% | EDGAR |
| SC 13G | 2014-02-12 | VANGUARD GROUP INC | Celldex Therapeutics, Inc. | 4,972,275 | 5.6% | EDGAR |
| SC 13G | 2014-02-11 | FRANKLIN RESOURCES INC | Celldex Therapeutics, Inc. | 7,930,026 | 9.0% | EDGAR |
| SC 13G/A | 2014-02-07 | PRUDENTIAL FINANCIAL INC | Celldex Therapeutics, Inc. | - | - | EDGAR |